| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2024 , Vol 62 , Num 1
In vitro anti-inflammatory activities of Tanacetum parthenium L. extract and its major metabolite parthenolide
1 Department of Pharmacognosy, School of Pharmacy, Istanbul Medipol University, 34810 Istanbul, Türkiye2 Department of Pharmaceutical Microbiology, School of Pharmacy, Istanbul Medipol University, 34810 Istanbul, Türkiye
3 Department of Pharmacognosy, Faculty of Pharmacy, Yeditepe University, 34755 Istanbul, Türkiye
4 Department of Pharmacognosy, Faculty of Pharmacy, Anadolu University, 26470 Eskisehir, Türkiye
DOI : 10.23893/1307-2080.APS6212 Viewed : 5111 - Downloaded : 2602 Tanacetum parthenium L. (Feverfew) is daisy-like Asteraceae plant carrying sesquiterpene lactones; used for the treatment of migraine and anti-inflammatory effect. This study aims to evaluate T. parthenium extract and major metabolite parthenolide for in vitro COX-1/COX-2, LOX inhibitory activity. The extract analyzed by HPTLC. To evaluate COX-1/COX-2 inhibition assays, studied with commercial kits (20µg/mL concentration for extract, 5 µg/mL for parthenolide). The major component of extract characterized as parthenolide. IC50 values for COX-1/COX-2 inhibition of extract were 10.45 and 9.81µg/mL, for parthenolide; 4.86 and 1.90µg/mL. SI values of T. parthenium extract and parthenolide were 0.93 and 0.39. Extract showed selective COX-2 inhibitory activity. The inhibition value of extract on LOX was 80% and inhibition value of parthenolide was 41.13%. The results suggested that T. parthenium extract showed selective potential for COX-2 enzyme inhibition. To the best of our knowledge, the extract was tested with COX-1, COX-2, and LOX enzymes for the first time. Keywords : COX, LOX, anti-inflammatory, Tanacetum parthenium, feverfew